Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-29 @ 7:13 AM
Study NCT ID:
NCT04007835
Status:
UNKNOWN
Last Update Posted:
2019-07-05
First Post:
2019-06-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Sponsor:
Guangdong Association of Clinical Trials
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-12
Completion Date Type:
ESTIMATED
First Submit Date:
2019-06-25
First Submit QC Date:
None
Study First Post Date:
2019-07-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-07-02
Last Update Post Date:
2019-07-05
Last Update Post Date Type:
ACTUAL